Progress in predicting human ADME parameters in silico

Journal of Pharmacological and Toxicological Methods

Volumn 44, Issue 1, 2000, Pages 251-272

  Ekins, Sean ^a   Waller, Chris L ^a   Swaan, Peter W ^b   Cruciani, Gabriele ^c   Wrighton, Steven A ^a   Wikel, James H ^a  

^a ELI LILLY AND COMPANY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

ADME; Catalyst; QSAR

Indexed keywords

AMOXICILLIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLIC ACID DERIVATIVE; CYTOCHROME P450; GLYCOPROTEIN P; PHENOTHIAZINE DERIVATIVE; PROPAFENONE; RESERPINE DERIVATIVE; SODIUM CHLORIDE; THIOXANTHENE DERIVATIVE; YOHIMBINE DERIVATIVE;

ARTICLE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG CLEARANCE; DRUG COST; DRUG INDUSTRY; DRUG PENETRATION; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG TRANSPORT; GENOTOXICITY; HUMAN; NONHUMAN; PREDICTION;

CATALYSIS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR CONFORMATION; PHARMACOKINETICS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034460173     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8719(00)00109-X     Document Type: Article

References (168)

1. Structure-property model for membrane partitioning of oligopeptides
2. Inhibition of monoamine oxidase-B by condensed pyridazines and pyrimidines: Effects of lipophilicity and structure-activity relationships
3. Absorption of peptide and peptidomimetic drugs
4. Predicting human oral bioavailability of a compound: Development of a novel quantitative structure-bioavailability relationship
5. Flexibility and stability of the structure of cytochromes P450 3A4 and BM-3
6. Molecular dynamics study of time-correlated protein domain motions and molecular flexibility: Cytochrome P450BM-3
7. Bile acid sequestrants
8. Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein
9. How to make drugs orally active: A substrate template for peptide transporter PepT1
10. Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption
11. Substrate specificty of the ileal and hepatic Na+/bile acid cotransporters of the rabbit: II. A reliable 3D QSAR pharmacophore model for the ileal Na+/bile acid cotransporter
12. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
13. A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line
14. New hydrogen-bond potential for use in determining energetically favourable binding sites of molecules of known structure
15. Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: In vitro studies of potential co-medication interactions
16. Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity
17. Application of MS-WHIM Descriptors: 3. Prediction of molecular properties
18. Genomic biology
19. Intestinal transport of B-lactam antibiotics: Analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux
20. AM1-based model system for estimation of brain/blood concentration ratios
21. On the connection between chemical constitution and physiological action
22. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia
23. Human and rat liver phenol sulfotransferase: Structure-activity relationships for phenolic substrates
24. Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance
25. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats
26. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena: 1. Prediction of intestinal absorption
27. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena: 2. Prediction of blood-brain barrier penetration
28. Computational methods for the prediction of 'drug-likeness'
29. Comparative molecular field analysis (CoMFA): 2. Toward its use with 3D-structural databases
30. A new set of principal properties for heteroaromatics obtained by GRID
31. Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk
32. The DYLOMMS method: Initial results from a comparative study of approaches to 3D QSAR
33. Comparative molecular field analysis (CoMFA): 1. Effect of shape on binding of steroids to carrier proteins
34. Predicting blood-brain barrier permeation from the three-dimensional molecular structure
35. VolSurf and its interest in structure-disposition relationships
36. Molecular fields in quantitative structure-permeation relationships: The VolSurf approach
37. Volsurf: A new tool for the pharmacokinetic optimization of lead compounds
38. Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b
39. Diversity measures for enhancing ADME admissibility of combinatorial libraries
40. Novel approach to predicting P450-mediated drug metabolism: Development of a combined protein and pharmacophore model for humaan cytochrome P450 2D6
41. A refined substrate model for human cytochrome P450 2D6
42. Extension of a predictive substrate model for human cytochrome P450 2D6
43. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein
44. Characterization of binding properties to human P-glycoprotein: Development of a [3H] verapamil radioligand-binding assay
45. Minimal molecular determinants of substrates for recognition by the intestinal peptide transporter
46. The importance of a nitrogen atom in modulators of multidrug resistance
47. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors
48. Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of inhibitors for CYP3A4
49. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors
50. Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of substrates for CYP2B6
51. Three dimensional quantitative structure activty relationship (3D-QSAR) analysis of CYP3A4 substrates
52. Three dimensional-quantitative structure activity relationship computational approaches for prediction of human in vitro intrinsic clearance
53. Autoactivation and activation of cytochrome P450s
54. Predicting drug-drug interactions in silico using pharmacophores: A paradigm for the next millenium
55. Representing metabolic pathway information: An object-orientated approach
56. Drug metabolism data: Past and present status
57. Quinolone antibacterial agents: Relationship between structure and in vitro inhibition of human cytochrome P450 isoform CYP1A2
58. Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers
59. m
60. Partial least squares regression: A tutorial
61. The design and molecular modeling of CNS drugs
62. Molecular haskeys: A novel method for molecular characterisation and its application for predicting important pharmaceutical properties of molecules
63. Computational procedure for determining energetically favourable binding sites on biologically important macromolecules
64. Molecular factors influencing drug transfer across the blood-brain barrier
65. 3D-QSAR: A current perspective
66. Molecular field derived descriptors for the multivariate modeling of pharmacokinetic data
67. Quantitative relationships between lipophilic character and drug metabolism
68. Quantitative structure-activity relationships of cytochrome P-450
69. Metabolism databases: Their use and value
70. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9
71. Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase
72. MDCK (Madin-Darby Canine Kidney) cells: A tool for membrane permeability screening
73. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
74. Compass: Predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark
75. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase)
76. Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9
77. Predicting the rates and regioselectivity of reactions mediated by the P450 superfamily
78. Parallel artificial membrane permeation assay in the description of passive absorption processes
79. An alternative method for the alignment of molecular structures: Maximizing electrostatic and steric overlap
80. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs
81. HINT: A new method of empirical hydrophobic field calculation for CoMFA
82. CYP3A4 drug interactions: Correlation of ten in vitro probe substrates
83. Different approaches toward an automatic structural alignment of drug molecules: Applications to sterol mimics, thrombin and thermolyisin inhibitors
84. Predicting the cytochrome P450 mediated metabolism of xenobiotics
85. Substrate specificity of the ileal and the hepatic Na(+)/bile acid cotransporters of the rabbit: I. Transport studies with membrane vesicles and cell lines expressing the cloned transporters
86. Predicting drug absorption from molecular surface properties based on molecular dynamics simulations
87. QS and 3D QSAR in drug design: Part 1. Methodology
88. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: Application to 10 extensively metabolized drugs
89. The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans
90. Structure-related inhibition of human hepatic caffeine N3-demethylation by naturally occuing flavanoids
91. Computational methods for the structural alignment of molecules
92. Quantitative structure-activity relationships in substrates, inducers, and inhibitors of cytochrome P4501 (CYP1)
93. Molecular modeling study of structural requirements for the oligopeptide transporter
94. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
95. Computation of brain-blood partitioning of organic solutes via free energy calculations
96. Prediction of brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least squares (PLS) modeling
97. Three dimensional structure-activity relationships
98. Inhibition of monoamine oxidase by pirlindole analogues: 3D-QSAR and CoMFA analysis
99. Molecular determinants of MAO selectivity in a series of indolylmethylamine derivatives: Biological activities, 3D-QSAR/CoMFA analysis, and computational simulation of ligand recognition
100. Design principles for orally bioavailable drugs
101. Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: Drugs and anaogs, stereoisomers and metabolites
102. A return to rational drug discovery: Computer-based model of cells, organs and systems in drug target identification
103. Theoretical calculation and prediction of intestinal absorption of drugs in humans using MolSurf parameterization and PLS statistics
104. Theoretical calculation and prediction of brain-blood partitioning of organic solutes using molsurf parameterization and PLS statistics
105. Development of predictive phamacokinetic simulation models for drug discovery
106. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and non specific binding to microsomes
107. Comparative molecular field analysis of steroid aromatase inhibitors
108. Theoretical and practical aspects of three-dimensional quantitative structure-activity relationships
109. Theoretical calculation and prediction of P-glycoprotein-interacting drugs using MolSurf parametrization and PLS statistics
110. QSAR and molecular modelling of catamphiphilic drugs able to modulate multidrug resistance in tumors
111. Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: A comparative molecular field analysis study
112. A comparative molecular field analysis of propafenone-type modulators of cancer multidrug resistance
113. Correlation of drug absorption with molecular surface properties
114. Evaluation of dynamic polar molecular surface area as a predictor of drug absorption: Comparison with other computational and experimental predictors
115. Polar molecular surface properties predict the intestinal absorption of drugs in humans
116. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance
117. Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance
118. The use of human in vitro metabolic parameters to explore the risk assessment of hazardous compounds: The case of ethylene dibromide
119. Comparative molecular field analysis of compounds with CYP2A5 binding affinity
120. Reversal of multidrug resistance by phenothiazines and structurally related compounds
121. A refined 3-dimensional QSAR of P4502C9
122. Commercial toxicology prediction systems: A regulatory perspective
123. Application of neural networks for the prediction of human pharmacokinetic parameters
124. Studies on propafenone-type modulators of multidrug resistance: VIII. Synthesis and pharmacological activity of indanon analogues
125. P-glycoprotein substrates and antagonists cluster into two distinct groups
126. The virtual cell
127. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells
128. Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements
129. Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques
130. How does P-glycoprotein recognize its substrates?
131. Prediction of drug permeability based on grid calculations
132. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone: Evidence for a third drug-binding site
133. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities
134. Structure-activity relationship of carbacephalosporins and cephalosporins: Antibacterial activity and interaction with the intestinal proton-dependent dipeptide transport carrier of Caco-2 cells
135. Virtual screening of intestinal permeability
136. Prediction of the intestinal absorption of endothelin receptor antagonists using three theoretical methods of increasing complexity
137. Hydrophobicity of HIV protease inhibitors by immobilized artificial membrane chromatography: Application and significance to drug transport
138. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: Molecular modeling and inhibition studies
139. A general approach for the prediction of the intestinal absorption of drugs: Regresssion analysis using the physiochemical properties and drug-membrane electrostatic interaction
140. Mapping the binding site of the small intestinal peptide carrier (PepT1) using comparative molecular field analysis
141. Molecular modeling of the intestinal bile acid carrier; a comparative molecular field analysis study
142. Molecular determinants of recognition for the intestinal peptide carrier
143. Molecular basis of P450 inhibition and activation
144. The hypocholesterolemic action of TA-7552 and its effects on cholesterol metabolism in the rat
145. A combined Hansch/free Wilson approach as predictive tool in QSAR studies on propafenone-type modulators of multidrug resistance
146. E-CELL: Software environment for whole-cell simulation
147. Estimation of Caco-2 cell permeability using calculated molecular descriptors
148. ALADDIN: An integrated tool for computer-assisted molecular design and pharmacophore recognition from geometric, steric and substructure searching of three-dimensional molecular structures
149. Modeling the cytochrome P450-mediated metabolism of volatile organic compounds (VOCs)
150. Ligand-based identification of environmental estrogens
151. 3-D QSAR of human immunodeficiency virus (I) protease inhibitors: I. A CoMFA study employing experimentally-determined alignment rules
152. HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: In vitro-in vivo correlation with permeability data from rats and humans
153. Synthesis and biological activity of bile acid-derived HMG-CoA reductase inhibitors. The role of 21-methyl in recognition of HMG-CoA reductase and the ileal bile acid transport system
154. Prediction of human intestinal absorption of drug compounds from molecular structure
155. Screening studies for metabolism and toxicology
156. Blood-brain barrier properties of human immunodeficiency virus antiretrovirals
157. Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds
158. QSAR model for drug human oral bioavailability